Abbott ID NOW is a molecular test, not an antigen test. It detects viral genetic material (RNA), which puts it in the same broad category as PCR. However, it doesn’t use the traditional PCR method. Instead, it relies on a different amplification technology called isothermal nucleic acid amplification, which achieves similar goals through a simpler, faster process.
This distinction matters because the test sits in a middle ground that confuses a lot of people. It’s more accurate than a rapid antigen test, faster than a lab-based PCR test, and uses a fundamentally different mechanism than both.
How ID NOW Differs From PCR and Antigen Tests
The FDA groups diagnostic tests into two main categories: molecular tests, which detect genetic material from a virus, and antigen tests, which detect proteins on the virus’s surface. ID NOW falls squarely into the molecular camp. It looks for RNA, not proteins.
Traditional PCR works by heating and cooling a sample repeatedly to double the amount of genetic material with each cycle. This requires a sophisticated laboratory instrument and typically takes hours. ID NOW skips the temperature cycling entirely. Its isothermal method amplifies genetic material at a single constant temperature, which is why it can deliver results in 13 minutes or less instead of requiring a lab with a several-hour turnaround. The tradeoff is a slight reduction in sensitivity compared to full laboratory PCR, particularly when viral loads are low.
Antigen tests, by contrast, use a completely different approach. They bind to proteins on the outside of the virus, similar to how a pregnancy test works. This makes them fast and cheap but less sensitive, especially early in infection when protein levels haven’t built up yet. ID NOW is significantly more accurate than antigen tests because amplifying genetic material can detect much smaller amounts of virus.
Accuracy Compared to Lab-Based PCR
In symptomatic patients, ID NOW agrees with standard lab PCR results about 91.7% of the time for positive cases and 98.4% of the time for negatives. That’s strong performance for a point-of-care test, though not quite as sensitive as a full lab PCR.
The gap narrows considerably when viral load is higher. When patients carry more virus (reflected by lower cycle threshold values in lab testing), ID NOW’s agreement with PCR climbs to 97.6% and reaches 99.4% at the highest viral loads. In practical terms, this means ID NOW is excellent at catching infections when people are most contagious, according to a study published in Microbiology Spectrum.
Where ID NOW shows a more meaningful gap is in asymptomatic testing. Among asymptomatic people who tested positive on lab PCR, ID NOW caught only about 69% to 83% of cases, depending on the study group. This makes sense: people without symptoms often carry less virus, and the isothermal method is less sensitive at detecting very small amounts of genetic material than the repeated amplification cycles of full PCR.
What the Test Experience Looks Like
ID NOW is an instrument-based test, meaning it runs on a small portable analyzer typically found in clinics, urgent care centers, pharmacies, and emergency departments. It’s not a home test. A healthcare worker collects a nasal, nasopharyngeal, or throat swab, inserts it into a cartridge, and places the cartridge into the ID NOW device. Results come back in 13 minutes or less, often while you wait.
This speed is the test’s main practical advantage. A standard lab PCR might take anywhere from several hours to a day or more once you factor in transport time and lab queues. ID NOW gives you a molecular-level result at the point of care, which is why it became widely used in settings where quick decisions matter, like emergency rooms and pre-procedure screening.
Beyond COVID-19
The ID NOW platform isn’t limited to COVID-19 testing. Abbott has developed separate test cartridges for influenza A and B and strep throat, all FDA-cleared and running on the same small instrument. Each cartridge uses the same isothermal amplification approach, just targeting different genetic sequences. This versatility makes the device useful year-round in clinical settings, particularly during respiratory virus season when distinguishing between flu, COVID-19, and strep based on symptoms alone is difficult.
When ID NOW Results Are Most Reliable
If you’re symptomatic and receive a positive ID NOW result, it’s highly reliable. The test’s specificity hovers around 98.4%, meaning false positives are rare. A negative result in a symptomatic person is also generally trustworthy, though there’s a small chance of a false negative, particularly very early in infection when viral levels are still building.
If you’re asymptomatic, a positive result is still meaningful, but a negative result carries more uncertainty. The test misses a larger proportion of low-viral-load infections in people without symptoms. In those situations, a follow-up lab PCR test may be worthwhile if there’s a strong reason to suspect infection, such as a known close exposure.